Neal Breit, MD
Endocrinology, Diabetes & Metabolism · Westwood, NJNPI 1558419630
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Shire North American Group Inc at 47.3% of the total. Reporting peaked in 2019 at $6,266 and has fallen 94.7% since, to $334 in 2025.
Across 122 payments — averaging $96.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$6K
- IBSA Pharma Inc.$4K
- Boehringer Ingelheim$544
- Amgen$531
- Novo Nordisk$271
- Lilly USA, LLC$158
- plus $651 from 14 others
What the payments were for
- Consulting fees$3,20027%
- Speaking & faculty fees$5,40046%
- Travel & lodging$6025%
- Food & beverage$2,55922%
- Gifts$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 11 | $5,590 |
| IBSA Pharma Inc. | 16 | $4,075 |
| Boehringer Ingelheim | 25 | $544 |
| Amgen | 9 | $531 |
| Novo Nordisk | 14 | $271 |
| Lilly USA, LLC | 5 | $158 |
| AstraZeneca | 11 | $144 |
| Mannkind Corporation | 4 | $98 |
| Abbott | 3 | $63 |
| Radius Health, Inc. | 4 | $55 |
| Merck | 3 | $42 |
| Amneal Pharmaceuticals LLC | 3 | $41 |
| Zealand Pharma US, Inc. | 3 | $40 |
| Kyowa Kirin, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| AbbVie | 2 | $25 |
| Antares Pharma, Inc. | 2 | $25 |
| Medtronic | 1 | $22 |
| Dexcom, Inc. | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,820 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 45 | $51,908 |
| TrulicityDulaglutide | 15 | $28,923 |
| RybelsusSemaglutide | 19 | $20,691 |
| OzempicSemaglutide | 11 | $14,714 |
| TradjentaLinagliptin | 16 | $13,750 |
| JanuviaSitagliptin Phosphate | 16 | $12,893 |
| SynthroidLevothyroxine Sodium | 38 | $3,952 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $3,738 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,811 |
| UnithroidLevothyroxine Sodium | 14 | $1,747 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $1,395 |
| Levothyroxine Sodium | 56 | $808 |
| Acarbose | 11 | $577 |
| Ezetimibe | 15 | $529 |
| Metformin Hcl | 48 | $344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $544 | $65,65961 claims |
| Novo NordiskRybelsus, Ozempic | $271 | $35,40630 claims |
| Lilly USA, LLCTrulicity | $158 | $28,92315 claims |
| MerckJanuvia, Janumet | $42 | $16,63129 claims |
| AbbVieSynthroid | $25 | $3,95238 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $41 | $2,55570 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Westwood
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.